TSI Pharmaceuticals was established as NPD (New Products Development) in 1988 in Brisbane, Australia, and has grown to supply and package an extensive range of non-scheduled, complementary, listed and registered products.

In 2012, NPD changed its name to TSI Pharmaceuticals, when the organisation officially became part of the TSI Group, an innovative producer of raw materials including but not limited to glucosamine, chondroitin and myHMB.

Merger provided access to worldwide innovation, economic purchasing and the vertical integration of raw materials.

TSI’s mission is bringing health to life and is now a world-class manufacturer of innovative and functional health products.

TSI supports customers in over 34 countries with state-of-the-art manufacturing, global sales, distribution and regulatory support. Our commitment is to employ state-of-the-art operations to deliver best-in-class products that are functional, efficacious and safe.